Life Extension Final Clerance Sale

Influenza References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. CDC (Centers for Disease Control and Prevention) Key Facts about Influenza (Flu) & Flu Vaccine. Last updated March 28, 2012. (2012b) Accessed 7/16/12 at: http://www.cdc.gov/flu/keyfacts.htm
  2. MedlinePlus. Flu. Available at: http://www.nlm.nih.gov/medlineplus/flu.html. Last updated October 12, 2012. Accessed October 17, 2012.
  3. NFID (National Foundation for Infectious Diseases). Influenza. Available at: http://www.nfid.org/idinfo/influenza. Accessed October 17, 2012.
  4. Ye J, Shao H, Perez DR. Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy. 2012;4(2):175-186.
  5. Clark NM, Lynch JP, 3rd. Influenza: epidemiology, clinical features, therapy, and prevention. Seminars in respiratory and critical care medicine. Aug 2011;32(4):373-392.
  6. CDC (Centers for Disease Control and Prevention). Seasonal Influenza (Flu). Estimating Seasonal Influenza-Associated Deaths in the United States: CDC Study Confirms Variability of Flu. Available at: http://www.cdc.gov/flu/about/disease/us_flu-related_deaths.htm?s_cid=cs_074. Last updated June 24, 2011c. Accessed October 17, 2012.
  7. Mgbemena V, Segovia JA, Chang TH, et al. Transactivation of Inducible Nitric Oxide Synthase Gene by Kruppel-like Factor 6 Regulates Apoptosis during Influenza A Virus Infection. J Immunol. 2012;18:18.
  8. NIH (National Institute of Health). The Patient Education Institute: X-Plain: Influenza-Flu (Reference Summary). Last Reviewed 4/30/2008. Accessed 6/28/12. Available at: http://www.nlm.nih.gov/medlineplus/tutorials/ influenza/id439102.pdf
  9. CDC (Centers for Disease Control and Prevention). Seasonal Influenza (Flu). Updated: 7/6/2011d. Accessed 10/15/2012 at http://www.cdc.gov/flu/about/qa/disease.htm.
  10. Falagas ME, Cholevas NV, Kapaskelis AM, Vouloumanou EK, Michalopoulos A, Rafailidis PI. Epidemiological aspects of 2009 H1N1 influenza: the accumulating experience from the Northern Hemisphere. Eur J ClinMicrobiol Infect Dis. 2010;29(11):1327-1347.
  11. Wu JT, Lee CK, Cowling BJ, Yuen KY. Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic. ProcNatlAcadSci U S A. 2010;107(7):3269-3274.
  12. Tang JW, Shetty N, Lam TT, Hon KL. Emerging, novel, and known influenza virus infections in humans. Infect Dis Clin North Am. 2010;24(3):603-617.
  13. Cao W, Kim JH, Chirkova T, et al. Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Rev Vaccines. 2011;10(11):1529-1537.
  14. Jefferson T, Demicheli D, di Pietrantonj C, Jones M and Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev. 2006;3:CD001265.
  15. NIAID (National Institute of Allergy and Infectious Diseases). Topics: Flu: Understanding Flu: Definitions and Overview. Updated August 08, 2011. Accessed 7/1/12. Available at: http://www.niaid.nih.gov/topics/Flu/understandingFlu/Pages/definitionsOverview.aspx
  16. NIH (National Institute of Health) MeSH Term definition: Influenza, Human. Accessed 7/6/12 (2012a). Available at: http://www.ncbi.nlm.nih.gov/mesh/68007251
  17. Kim TS, Sun J, Braciale TJ. T cell responses during influenza infection: getting and keeping control. Trends in immunology. May 2011;32(5):225-231.
  18. Sanders CJ, Doherty PC, Thomas PG. Respiratory epithelial cells in innate immunity to influenza virus infection. Cell and tissue research. Jan 2011;343(1):13-21.
  19. Snelgrove RJ, Godlee A, Hussell T. Airway immune homeostasis and implications for influenza-induced inflammation. Trends in immunology. Jul 2011;32(7):328-334.
  20. Shobugawa Y, Wiafe SA, Saito R, et al. Novel measurement of spreading pattern of influenza epidemic by using weighted standard distance method: retrospective spatial statistical study of influenza, Japan, 1999-2009. Int J Health Geogr. 2012;11(1):20.
  21. Hayden F. (2011) Chapter 372: Influenza (pg. 2095). In: Goldman L. (Ed.), Goldman's Cecil Medicine (24th ed). Saunders, An Imprint of Elsevier.
  22. Gouarin S, Vabret A, Dina J, et al. Study of influenza C virus infection in France. J Med Virol. 2008;80(8):1441-1446.
  23. Afilalo M, Stern E, Oughton M. Evaluation and management of seasonal influenza in the emergency department. Emerg Med Clin North Am. 2012;30(2):271-305.
  24. CDC (Centers for Disease Control and Prevention) How Flu Spreads. Last updated June 30, 2011 (2011a). Accessed 7/19/12 at: http://www.cdc.gov/flu/about/disease/spread.htm
  25. NIH (National Institute of Health) MeSH Term definition: Pandemic. Accessed 7/6/12 (2012b). Available at: http://www.ncbi.nlm.nih.gov/mesh?term=pandemic
  26. Gasparini R, Amicizia D, Lai PL, Panatto D. Aflunov((R)): a prepandemic influenza vaccine. Expert Rev Vaccines. 2012;11(2):145-157.
  27. Bavagnoli L, Maga G. The 2009 influenza pandemic: promising lessons for antiviral therapy for future outbreaks. Curr Med Chem. 2011;18(35):5466-5475.
  28. Taubenberger JK, Kash JC. Insights on influenza pathogenesis from the grave. Virus Res. 2011;162(1-2):2-7.
  29. Michaelis M, Doerr HW, Cinatl J, Jr. Of chickens and men: avian influenza in humans. CurrMol Med. 2009;9(2):131-151.
  30. Combes A, Pellegrino V. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1)-associated acute respiratory distress syndrome. SeminRespirCrit Care Med. 2011;32(2):188-194.
  31. van Ierssel SH, Leven M, Jorens PG. Severe influenza A(H1N1)2009 infection: a single centre experience and review of the literature. ActaClin Belg. 2012;67(1):1-6.
  32. Bai L, Cao B, Wang C. Influenza A pandemic (H1N1) 2009 virus infection. Chin Med J. 2011;124(20):3399-3402.
  33. WHO (World Health Organization) Pandemic (H1N1) 2009–update 112. Accessed 6/30/12. Available at: www.who.int/csr/don/2010_08_06/en/index.html
  34. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;26:26.
  35. Seidman JC, Richard SA, Viboud C, Miller MA. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respi Viruses. 2012;6(1):52-62.
  36. Atmar RL, Patel SM, Keitel WA. Intanza((R)): a new intradermal vaccine for seasonal influenza. Expert Rev Vaccines. 2010;9(12):1399-1409.
  37. Pedersen C. [Convalescence and sick leave after influenza]. UgeskrLaeger. 2009;171(40):2913-2915.
  38. Yoo BK. How to improve influenza vaccination rates in the U.S. J Prev Med Public Health. 2011;44(4):141-148.
  39. Music T. Protecting patients, protecting healthcare workers: a review of the role of influenza vaccination. IntNurs Rev. 2012;59(2):161-167.
  40. Lynch JP, 3rd, Walsh EE. Influenza: evolving strategies in treatment and prevention. SeminRespirCrit Care Med. 2007;28(2):144-158.
  41. Lambe T, Spencer AJ, Mullarkey CE, et al. T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalent-inactivated Influenza Vaccine. Pediatr Infect Dis J. 2012;31(6):e86-91.
  42. Mao L, Yang Y, Qiu Y. Annual economic impacts of seasonal influenza on US counties: Spatial heterogeneity and patterns. Int J Health Geogr. 2012;11(1):16.
  43. Banzhoff A, Stoddard J. Effective influenza vaccines for children: A critical unmet medical need and a public health priority. Hum VaccinImmunother. 2012;8:3.
  44. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the Eye of the Cytokine Storm. Microbiology and Molecular Biology Reviews. March 1, 2012 2012;76(1):16-32.
  45. Danese S, Dejana E, Fiocchi C. Immune Regulation by Microvascular Endothelial Cells: Directing Innate and Adaptive Immunity, Coagulation, and Inflammation. The Journal of Immunology. May 15, 2007 2007;178(10):6017-6022.
  46. Schmolke M, Viemann D, Roth J, Ludwig S. Essential impact of NF-kappaB signaling on the H5N1 influenza A virus-induced transcriptome. J Immunol. 2009;183(8):5180-5189.
  47. Walsh KB, Teijaro JR, Rosen H, Oldstone MB. Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. Immunol Res. 2011a;51(1):15-25.
  48. Phung TT, Sugamata R, Uno K, et al. Key role of regulated upon activation normal T-cell expressed and secreted, nonstructural protein1 and myeloperoxidase in cytokine storm induced by influenza virus PR-8 (A/H1N1) infection in A549 bronchial epithelial cells. MicrobiolImmunol. 2011;55(12):874-884.
  49. Teijaro JR, Walsh KB, Cahalan S, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell. 2011;146(6):980-991.
  50. Ma J, Dushoff J, Earn DJ. Age-specific mortality risk from pandemic influenza. J Theor Biol. 2011;288:29-34.
  51. Us D. [Cytokine storm in avian influenza]. Mikrobiyol Bul. 2008;42(2):365-380.
  52. Gao R, Dong L, Dong J, et al. A systematic molecular pathology study of a laboratory confirmed H5N1 human case. PLoS One. 2010;5(10).
  53. Walsh KB, Teijaro JR, Wilker PR, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. ProcNatlAcadSci U S A. 2011b;108(29):12018-12023.
  54. Rowe CA, Nantz MP, Bukowski JF, Percival SS. Specific formulation of Camellia sinensis prevents cold and flu symptoms and enhances gamma,delta T cell function: a randomized, double-blind, placebo-controlled study. J Am CollNutr. 2007;26(5):445-452.
  55. Majdalawieh AF, Hmaidan R, Carr RI. Nigella sativa modulates splenocyte proliferation, Th1/Th2 cytokine profile, macrophage function and NK anti-tumor activity. Journal of ethnopharmacology. Sep 15 2010;131(2):268-275.
  56. Salem ML, Hossain MS. Protective effect of black seed oil from Nigella sativa against murine cytomegalovirus infection. International journal of immunopharmacology. Sep 2000;22(9):729-740.
  57. Salem ML, Alenzi FQ, Attia WY. Thymoquinone, the active ingredient of Nigella sativa seeds, enhances survival and activity of antigen-specific CD8-positive T cells in vitro. British journal of biomedical science. 2011;68(3):131-137.
  58. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. International immunopharmacology. Dec 2005;5(13-14):1749-1770.
  59. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134(6):1129-40.
  60. Russell CA, Jones TC, Barr IG, et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine. 2008;12(26):D31-34.
  61. Ravin NV, Kotlyarov RY, Mardanova ES, et al. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry. 2012;77(1):33-40.
  62. Lang PO, Mendes A, Socquet J, Assir N, Govind S, Aspinall R. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clinical interventions in aging. 2012;7:55-64.
  63. Ornskov Pedersen L, Lund KB, Nielsen TJ, Hansen J, Tougaard NH, Andersen JH. [Unclear effect of influenza vaccination in healthy adults]. Ugeskrift for laeger. Mar 26 2012;174(13):859-861.
  64. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet infectious diseases. Jan 2012;12(1):36-44.
  65. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Human vaccines &immunotherapeutics. Jan 2012;8(1):81-88.
  66. Allsup SJ, Gosney M, Regan M, Haycox A, Fear S, Johnstone FC. Side effects of influenza vaccination in healthy older people: a randomised single-blind placebo-controlled trial. Gerontology. Nov-Dec 2001;47(6):311-314.
  67. Stebbins S, Downs JS, Vukotich CJ, Jr. The effect of grade on compliance using nonpharmaceutical interventions to reduce influenza in an urban elementary school setting. J Public Health ManagPract. 2011;17(1):65-71.
  68. Yardley L, Miller S, Teasdale E, Little P. Using mixed methods to design a web-based behavioural intervention to reduce transmission of colds and flu. J Health Psychol. 2011;16(2):353-364.
  69. Mayo Clinic. Influenza (flu): Prevention. Last updated Aug. 20, 2011. Accessed 7/19/12 at: www.mayoclinic.com/health/influenza/ds00081/dsection=prevention
  70. MD Consult. Influenza. Updated 10/12/2012 Accessed 10/16/2012 at: http://www.mdconsult.com/das/pdxmd/body/373143450-3/0?type=med&eid=9-u1.0-_1_mt_1014549#33988
  71. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep. 2008;57(RR-7):1-60.
  72. Ebell MH. Diagnosing and treating patients with suspected influenza. Am Fam Physician. 2005;72(9):1789-1792.
  73. Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012;156(7):512-524.
  74. MD Consult. Oseltamivir. Updated 9/6/2011. Accessed 10/19/2012 at: http://www.mdconsult.com/das/pharm/body/374831631-11/0/full/2450
  75. MD Consult. Chapter 53 – Antiviral Agents. In: Shannon: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th ed. Copyright 2007. Accessed 10/22/2012 at: http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-0-7216-0693-4..50058-X&isbn=978-0-7216-0693-4&sid=1370781732&uniqId=375410144-6#4-u1.0-B978-0-7216-0693-4..50058-X--cesec49
  76. MD Consult. Amantadine. Updated 10/07/2009. Accessed 10/19/2012 at: http://www.mdconsult.com/das/pharm/body/374831631-12/0/full/20
  77. CDC. High Levels of Adamantane Resistance Among Influenza A (H3N2) Viruses and Interim Guidelines for Use of Antiviral Agents --- United States, 2005--06 Influenza Season. Reviewed 1/19/2006. Accessed 10/22/2012 at: http://www.cdc.gov/MMWR/PREVIEW/mmwrhtml/mm5502a7.htm
  78. CDC. Antiviral Drug-Resistance among Influenza Viruses. Guidance on the Use of Influenza Antiviral Agents. Updated: 9/1/2011(f). Accessed 10/22/2012 at: http://www.cdc.gov/flu/professionals/antivirals/antiviral-drug-resistance.htm
  79. Fediakina IT, Shchelkanov M, Deriabin PG, et al. [Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture]. AntibiotKhimioter. 2011;56(3-4):3-9.
  80. Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc. 2011;86(10):1009-1026.
  81. Schleiss M. (2011) Chapter 237: Principles of Antiviral Therapy: Antivirals Used for Respiratory Viral Infections: Ribavirin (pg. 1069.e9). In: Kliegman R. (Ed.), Nelson Textbook of Pediatrics (19th ed). Saunders, An Imprint of Elsevier.
  82. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008;78(1):91-102.
  83. MMWR. Severe influenza among children and young adults with neurologic and neurodevelopmental conditions - Ohio, 2011. MMWR Morb Mortal Wkly Rep. 2012;60(51-52):1729-1733.
  84. Gaglia MA, Jr., Cook RL, Kraemer KL, Rothberg MB. Patient knowledge and attitudes about antiviral medication and vaccination for influenza in an internal medicine clinic. Clin Infect Dis. 2007;45(9):1182-1188.
  85. CDC 2011-2012 influenza antiviral medications. J PractNurs. 2011b;61(3):21-23.
  86. Bijl D. Pandemic influenza vaccines and neuraminidase inhibitors: efficacy and side effects. Int J Risk Saf Med. 2011;23(2):65-71.
  87. CDC (Centers for Disease Control and Prevention) Antibiotics Aren't Always the Answer. Last updated Feb. 27, 2012. (2012a) Accessed 7/19/12 at: http://www.cdc.gov/Features/GetSmart/
  88. Kubecova M, Kolostova K, Pinterova D, Kacprzak G, Bobek V. Cimetidine: an anticancer drug? Eur J Pharm Sci. 2011;42(5):439-444.
  89. Scheinfeld N. Cimetidine: a review of the recent developments and reports in cutaneous medicine. Dermatol Online J. 2003;9(2):4.
  90. Shin JS, Abah U. Is routine stress ulcer prophylaxis of benefit for patients undergoing cardiac surgery? Interact CardiovascThorac Surg. 2012;14(5):622-628.
  91. Arae K, Oboki K, Ohno T, et al. Cimetidine enhances antigen-specific IgE and Th2 cytokine production. Allergol Int. 2011;60(3):339-344.
  92. Zhang W, Wang J, Su B, et al. Cimetidine augments Th1/Th2 dual polarized immune responses to recombinant HBV antigens. Vaccine. 2011;29(29-30):4862-4868.
  93. Wang J, Su B, Ding Z, Du X, Wang B. Cimetidine enhances immune response of HBV DNA vaccination via impairment of the regulatory function of regulatory T cells. BiochemBiophys Res Commun. 2008;372(3):491-496.
  94. Stefani M, Bottino G, Fontenelle E, Azulay DR. [Efficacy comparison between cimetidine and zinc sulphate in the treatment of multiple and recalcitrant warts]. An Bras Dermatol. 2009;84(1):23-29.
  95. Kumar A. Cimetidine: an immunomodulator. DICP : the annals of pharmacotherapy. Mar 1990;24(3):289-295.
  96. Goldfine AB. Statins: is it really time to reassess benefits and risks? The New England journal of medicine. May 10 2012;366(19):1752-1755.
  97. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis. 2012;205(1):13-19.
  98. Almuti K, Rimawi R, Spevack D, Ostfeld RJ. Effects of statins beyond lipid lowering: potential for clinical benefits. Int J Cardiol. 2006;109(1):7-15.
  99. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest. 2007;131(4):1006-1012.
  100. Siu E, Campitelli MA, Kwong JC. Physical activity and influenza-coded outpatient visits, a population-based cohort study. PLoS One. 2012;7(6):21.
  101. Gardner EM, Beli E, Clinthorne JF, Duriancik DM. Energy intake and response to infection with influenza. Annu Rev Nutr. 2011;31:353-367.
  102. Louria DB. Undernutrition can affect the invading microorganism. Clin Infect Dis. 2007;45(4):470-474.
  103. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J ClinVirol. 2011;50(3):194-200.
  104. Grant WB, Goldstein M, Mascitelli L. Ample evidence exists from human studies that vitamin D reduces the risk of selected bacterial and viral infections. ExpBiol Med. 2010;235(12):1395-1396.
  105. Berry DJ, Hesketh K, Power C, Hypponen E. Vitamin D status has a linear association with seasonal infections and lung function in British adults. Br J Nutr. 2011;106(9):1433-40.
  106. Cannell JJ. The difference between a prophet and a madman. Br J Nutr. 2011;106(9):1317-8.
  107. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice. Altern Med Rev. 2008;13(1):6-20.
  108. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. The American journal of clinical nutrition. May 2010;91(5):1255-1260.
  109. Aloia JF, Li-Ng M. Re: epidemic influenza and vitamin D. Epidemiology and infection. Oct 2007;135(7):1095-1096; author reply 1097-1098.
  110. Shaman J, Jeon CY, Giovannucci E, Lipsitch M. Shortcomings of vitamin D-based model simulations of seasonal influenza. PLoS One. 2011;6(6):3.
  111. Grant WB, Giovannucci E. The possible roles of solar ultraviolet-B radiation and vitamin D in reducing case-fatality rates from the 1918-1919 influenza pandemic in the United States. Dermato-endocrinology. Jul 2009;1(4):215-219.
  112. Heimer KA, Hart AM, Martin LG, Rubio-Wallace S. Examining the evidence for the use of vitamin C in the prophylaxis and treatment of the common cold. J Am Acad Nurse Pract. 2009;21(5):295-300.
  113. Jariwalla RJ, and Harakeh S. Antiviral and Immunomodulatory Activities of Ascorbic Acid. [In eng] SubcellBiochem. 1996 25(213-31).
  114. Anderson R. The Immunostimulatory, Antiinflammatory and Anti-Allergic Properties of Ascorbate. [In eng] AdvNutr Res. 1984 6(19-45.
  115. Holt S. Hype around high-dose vitamin C is unjustified: N Z Med J. 2010 Oct 15;123(1324):109-10.
  116. Gorton HC, Jarvis K. The effectiveness of vitamin C in preventing and relieving the symptoms of virus-induced respiratory infections. J Manipulative PhysiolTher. 1999;22(8):530-533.
  117. Eide DJ. The oxidative stress of zinc deficiency. Metallomics. 2011;3(11):1124-1129.
  118. Classen HG, Grober U, Low D, Schmidt J, Stracke H. [Zinc deficiency. Symptoms, causes, diagnosis and therapy]. Med Monatsschr Pharm. 2011;34(3):87-95.
  119. Roxas M, Jurenka J. Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Altern Med Rev. 2007;12(1):25-48.
  120. Hemila H. Zinc lozenges may shorten the duration of colds: a systematic review. The open respiratory medicine journal. 2011;5:51-58.
  121. Hoffmann PR, Berry MJ. The influence of selenium on immune responses. Molecular Nutrition & Food Research. 2008;52(11):1273-1280.
  122. Goldson AJ, Fairweather-Tait SJ, Armah CN, et al. Effects of selenium supplementation on selenoprotein gene expression and response to influenza vaccine challenge: a randomised controlled trial. PLoS One. 2011;6(3).
  123. Jaspers I, Zhang W, Brighton LE, Carson JL, Styblo M, Beck MA. Selenium deficiency alters epithelial cell morphology and responses to influenza. Free RadicBiol Med. 2007;42(12):1826-1837.
  124. Stỳblo M, Walton FS, Harmon AW, Sheridan PA, Beck MA. Activation of superoxide dismutase in selenium-deficient mice infected with influenza virus. J Trace Elem Med Biol. 2007;21(1):52-62.
  125. Beck MA, Levander OA, Handy J. Selenium deficiency and viral infection. J Nutr. 2003;133(5 Suppl 1):1463S-1467S.
  126. Yu L, Sun L, Nan Y, Zhu LY. Protection from H1N1 influenza virus infections in mice by supplementation with selenium: a comparison with selenium-deficient mice. Biol Trace Elem Res. 2011;141(1-3):254-261.
  127. Dror DK, Allen LH. Vitamin E deficiency in developing countries. Food Nutr Bull. 2011;32(2):124-143.
  128. Han SN, Meydani SN. Antioxidants, cytokines, and influenza infection in aged mice and elderly humans. J Infect Dis. 2000;182(1):S74-80.
  129. Orsi N. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals. 2004;17(3):189-196.
  130. Waarts BL, Aneke OJ, Smit JM, et al. Antiviral Activity of Human Lactoferrin: Inhibition of Alphavirus Interaction with Heparan Sulfate. [In eng] Virology. 2005 Mar 15; 333(2): 284-92.
  131. Berlutti F, Pantanella F, Natalizi T, Frioni A, Paesano R, Polimeni A, Valenti P. Antiviral properties of lactoferrin--a natural immunity molecule. Molecules. 2011;16(8):6992-7018.
  132. Ozgen M, Scheerens JC, Reese RN, Miller RA. Total phenolic, anthocyanin contents and antioxidant capacity of selected elderberry (Sambucuscanadensis L.) accessions. Pharmacogn Mag. 2010;6(23):198-203.
  133. Zakay-Rones Z, Thom E, Wollan T, Wadstein J. Randomized study of the efficacy and safety of oral elderberry extract in the treatment of influenza A and B virus infections. J Int Med Res. 2004;32(2):132-140.
  134. Roschek B, Jr., Fink RC, McMichael MD, Li D, Alberte RS. Elderberry flavonoids bind to and prevent H1N1 infection in vitro. Phytochemistry. 2009;70(10):1255-1261.
  135. Cooper R. Green tea and theanine: health benefits. Int J Food SciNutr. 2012;1:90-97.
  136. Park M, Yamada H, Matsushita K, et al. Green tea consumption is inversely associated with the incidence of influenza infection among schoolchildren in a tea plantation area of Japan. J Nutr. 2011;141(10):1862-1870.
  137. Guralnik M, Rosenbloom RA, Petteruti MP, Lefante C. Limitations of current prophylaxis against influenza virus infection. Am J Ther. 2007;14(5):449-454.
  138. Akramiene D, Kondrotas A, Didziapetriene J, Kevelaitis E. Effects of beta-glucans on the immune system. Medicina. 2007;43(8):597-606.
  139. Medeiros SD, Cordeiro SL, Cavalcanti JE, Melchuna KM, Lima AM, Filho IA, . . . Sales VS. Effects of Purified Saccharomyces cerevisiae (1-->3)-beta-Glucan on Venous Ulcer Healing. International journal of molecular sciences. 2012;13(7):8142-8158.
  140. Cordeiro LM, Reinhardt VD, Iacomini M. Glucomannan and branched (1-->3)(1-->6) beta-glucan from the aposymbiotically grown Physciakalbiimycobiont. Phytochemistry. Sep 13 2012.
  141. Pence BD, Hester SN, Donovan SM, Woods JA. Dietary whole glucan particles do not affect antibody or cell-mediated immune responses to influenza virus vaccination in mice. Immunol Invest. 2012;41(3):275-289.
  142. Jung K, Ha Y, Ha SK, et al. Antiviral effect of Saccharomyces cerevisiae beta-glucan to swine influenza virus by increased production of interferon-gamma and nitric oxide. J Vet Med B Infect Dis Vet Public Health. 2004;51(2):72-76.
  143. Xiao Z, Trincado CA, Murtaugh MP. Beta-glucan enhancement of T cell IFNgamma response in swine. Vet ImmunolImmunopathol. 2004 Dec 8;102(3):315-20.
  144. Yang S, Evens AM, Prachand S, et al. Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographispaniculata. Clin Cancer Res. 2010;16(19):4755-4768.
  145. Akbar S. Andrographispaniculata: a review of pharmacological activities and clinical effects. Altern Med Rev. 2011;16(1):66-77.
  146. Ji LL, Wang Z, Dong F, Zhang WB, Wang ZT. Andrograpanin, a compound isolated from anti-inflammatory traditional Chinese medicine Andrographispaniculata, enhances chemokine SDF-1alpha-induced leukocytes chemotaxis. Journal of cellular biochemistry. Aug 1 2005;95(5):970-978.
  147. Naik SR, Hule A. Evaluation of immunomodulatory activity of an extract of andrographolides from Andographispaniculata. Planta Med. 2009;75(8):785-791.
  148. Kulichenko LL, Kireyeva LV, Malyshkina EN, Wikman G. A randomized, controlled study of Kan Jang versus amantadine in the treatment of influenza in Volgograd. Journal of herbal pharmacotherapy. 2003;3(1):77-93.
  149. Gilliland SE, Morelli L, Reid G. Health and Nutritional Properties of Probiotics in Food Including Powder Milk With Live Lactic Acid Bacteria. Rome, Italy: Food and Agriculture Organization of the United Nations World Health Organization; 2001. Available at: ftp://ftp.fao.org/es/esn/food/probio_report_en.pdf. Accessed July 19, 2012
  150. MacDonald TT, Bell I. Probiotics and the immune response to vaccines. ProcNutr Soc. 2010;69(3):442-446.
  151. Leyer GJ, Li S, Mubasher ME, Reifer C, Ouwehand AC. Probiotic Effects on Cold and Influenza-Like Symptom Incidence and Duration in Children. Pediatrics. August 2009 2009;124(2):e172-e179.
  152. de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. AdvBiochemEngBiotechnol. 2008;111:1-66.
  153. Wolvers D, Antoine JM, Myllyluoma E, Schrezenmeir J, Szajewska H, Rijkers GT. Guidance for substantiating the evidence for beneficial effects of probiotics: prevention and management of infections by probiotics. J Nutr. 2010;140(3):27.
  154. Vouloumanou EK, Makris GC, Karageorgopoulos DE, Falagas ME. Probiotics for the prevention of respiratory tract infections: a systematic review. Int J Antimicrob Agents. 2009;34(3):28.
  155. Baron M. A patented strain of Bacillus coagulans increased immune response to viral challenge. Postgrad Med. 2009;121(2):114-118.
  156. Kimmel M, Keller D, Farmer S, Warrino DE. A controlled clinical trial to evaluate the effect of GanedenBC(30) on immunological markers. Methods Find ExpClinPharmacol. 2010;32(2):129-132.
  157. Bosch M, Mendez M, Perez M, Farran A, Fuentes MC, Cune J. Lactobacillus plantarum CECT7315 and CECT7316 stimulate immunoglobulin production after influenza vaccination in elderly. Nutr Hosp. 2012;27(2):504-509.
  158. Bao X, Liu C, Fang J, Li X. Structural and immunological studies of a major polysaccharide from spores of Ganodermalucidum (Fr.) Karst. Carbohydrate research. May 8 2001;332(1):67-74.
  159. Xu Z, Chen X, Zhong Z, Chen L, Wang Y. Ganodermalucidum polysaccharides: immunomodulation and potential anti-tumor activities. The American journal of Chinese medicine. 2011;39(1):15-27.
  160. Yeh CH, Chen HC, Yang JJ, Chuang WI, Sheu F. Polysaccharides PS-G and protein LZ-8 from Reishi (Ganodermalucidum) exhibit diverse functions in regulating murine macrophages and T lymphocytes. Journal of agricultural and food chemistry. Aug 11 2010;58(15):8535-8544.
  161. Karaman M, Jovin E, Malbasa R, Matavuly M, Popovic M. Medicinal and edible lignicolous fungi as natural sources of antioxidative and antibacterial agents. Phytotherapy research : PTR. Oct 2010;24(10):1473-1481.
  162. Iwatsuki K, Akihisa T, Tokuda H, Ukiya M, Oshikubo M, Kimura Y, . . . Nishino H. Lucidenic acids P and Q, methyl lucidenate P, and other triterpenoids from the fungus Ganodermalucidum and their inhibitory effects on Epstein-Barr virus activation. Journal of natural products. Dec 2003;66(12):1582-1585.
  163. Li Z, Liu J, Zhao Y. Possible mechanism underlying the antiherpetic activity of a proteoglycan isolated from the mycelia of Ganodermalucidum in vitro. Journal of biochemistry and molecular biology. Jan 31 2005;38(1):34-40.
  164. Yoon SY, Eo SK, Kim YS, Lee CK, Han SS. Antimicrobial activity of Ganodermalucidum extract alone and in combination with some antibiotics. Archives of pharmacal research. Dec 1994;17(6):438-442.
  165. Eo SK, Kim YS, Lee CK, Han SS. Antiherpetic activities of various protein bound polysaccharides isolated from Ganodermalucidum. Journal of ethnopharmacology. Dec 15 1999a;68(1-3):175-181.
  166. Eo SK, Kim YS, Lee CK, Han SS. Antiviral activities of various water and methanol soluble substances isolated from Ganodermalucidum. Journal of ethnopharmacology. Dec 15 1999b;68(1-3):129-136.
  167. Li YQ, Wang SF. Anti-hepatitis B activities of ganoderic acid from Ganodermalucidum. Biotechnology letters. Jun 2006;28(11):837-841.
  168. el-Mekkawy S, Meselhy MR, Nakamura N, Tezuka Y, Hattori M, Kakiuchi N, . . . Otake T. Anti-HIV-1 and anti-HIV-1-protease substances from Ganodermalucidum. Phytochemistry. Nov 1998;49(6):1651-1657.
  169. Eo SK, Kim YS, Lee CK, Han SS. Possible mode of antiviral activity of acidic protein bound polysaccharide isolated from Ganodermalucidum on herpes simplex viruses. Journal of ethnopharmacology. Oct 2000;72(3):475-481.
  170. Oh KW, Lee CK, Kim YS, Eo SK, Han SS. Antiherpetic activities of acidic protein bound polysacchride isolated from Ganodermalucidum alone and in combinations with acyclovir and vidarabine. Journal of ethnopharmacology. Sep 2000;72(1-2):221-227.
  171. Hijikata Y, Yasuhara A, Sahashi Y. Effect of an herbal formula containing Ganodermalucidum on reduction of herpes zoster pain: a pilot clinical trial. The American journal of Chinese medicine. 2005;33(4):517-523.
  172. Hijikata Y, Yamada S, Yasuhara A. Herbal mixtures containing the mushroom Ganodermalucidum improve recovery time in patients with herpes genitalis and labialis. Journal of alternative and complementary medicine (New York, N.Y.). Nov 2007;13(9):985-987.
  173. Romanutti C, Bruttomesso AC, Castilla V, Galagovsky LR, Wachsman MB. Anti-adenovirus activity of epiandrosterone and dehydroepiandrosterone derivatives. Chemotherapy. 2010;56(2):158-165.
  174. El Kihel L. Oxidative metabolism of dehydroepiandrosterone (DHEA) and biologically active oxygenated metabolites of DHEA and epiandrosterone (EpiA)--recent reports. Steroids. 2012;77(1-2):10-26.
  175. Torres NI, Castilla V, Bruttomesso AC, Eiras J, Galagovsky LR, Wachsman MB. In vitro antiviral activity of dehydroepiandrosterone, 17 synthetic analogs and ERK modulators against herpes simplex virus type 1. Antiviral Res. 2012;95(1):37-48.
  176. Kuehn CC, Oliveira LG, Santos CD, Augusto MB, Toldo MP, do Prado JC, Jr. Prior and concomitant dehydroepiandrosterone treatment affects immunologic response of cultured macrophages infected with Trypanosomacruzi in vitro? Vet Parasitol. 2011;177(3-4):242-246.
  177. Padgett DA, MacCallum RC, Loria RM, Sheridan JF. Androstenediol-induced restoration of responsiveness to influenza vaccination in mice. J Gerontol A BiolSci Med Sci. 2000b;55(9):B418-424.
  178. Prom-Wormley EC, York TP, Jacobson KC, et al. Genetic and environmental effects on diurnal dehydroepiandrosterone sulfate concentrations in middle-aged men. Psychoneuroendocrinology. 2011;36(10):1441-1452.
  179. Caetano LC, Santello FH, Del VecchioFilipin M, et al. Trypanosomacruzi: dehydroepiandrosterone (DHEA) and immune response during the chronic phase of the experimental Chagas' disease. Vet Parasitol. 2009;163(1-2):27-32.
  180. Powell JM, Sonnenfeld G. The effects of dehydroepiandrosterone (DHEA) on in vitro spleen cell proliferation and cytokine production. J Interferon Cytokine Res. 2006;26(1):34-39.
  181. Corsini E, Vismara L, Lucchi L, et al. High interleukin-10 production is associated with low antibody response to influenza vaccination in the elderly. J Leukoc Biol. 2006;80(2):376-82.
  182. Degelau J, Guay D, Hallgren H. The effect of DHEAS on influenza vaccination in aging adults. Journal of the American Geriatrics Society. Jun 1997;45(6):747-751.
  183. Khorram O, Vu L, Yen SS. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. The journals of gerontology. Series A, Biological sciences and medical sciences. Jan 1997;52(1):M1-7.
  184. Srinivasan V, Mohamed M, Kato H. Melatonin in bacterial and viral infections with focus on sepsis: a review. Recent Pat EndocrMetab Immune Drug Discov. 2012;6(1):30-39.
  185. Arushanian EB, Beier EV. [Immunotropic properties of pineal melatonin]. EkspKlinFarmakol. 2002;65(5):73-80.
  186. Boga JA, Coto-Montes A, Rosales-Corral SA, Tan DX, Reiter RJ. Beneficial actions of melatonin in the management of viral infections: a new use for this "molecular handyman"? Rev Med Virol. 2012;18(10).
  187. Bonilla E, Valero N, Chacin-Bonilla L, Medina-Leendertz S. Melatonin and viral infections. J Pineal Res. 2004;36(2):73-79.
  188. da Silveira Cruz-Machado S, Pinato L, Tamura EK, Carvalho-Sousa CE, Markus RP. Glia-Pinealocyte Network: The Paracrine Modulation of Melatonin Synthesis by Tumor Necrosis Factor (TNF). PLoS One. 2012;7(7):2.
  189. Srinivasan V, Maestroni G, Cardinali D, Esquifino A, Perumal SP, Miller S. Melatonin, immune function and aging. Immunity & Ageing. 2005;2(1):17.
  190. Utah Dept. Health. Difference Between Cold and Flu Symptoms. 8/2010. Availabel at: http://health.utah.gov/epi/diseases/flu/ColdvsFlu.pdf Accessed 8/27/2012.
  191. CDC. Cold Versus Flu. 2/8/2011e. Available at: http://www.cdc.gov/flu/about/qa/coldflu.htmAccessed 8/24/2012.
  192. Oklahoma State Dept. of Health. Cold vs. Flu: Know the difference. 09/2011. Available at: http://www.ok.gov/health/documents/Cold%20vs%20Flu%20Know%20the%20Difference.pdf Accessed: 8/27/2012.